Table 1.
Patient demographic and clinical characteristics
| n = 457 | ||
|---|---|---|
| Sex | ||
| Male, n (%) | 172 (37.6) | |
| Female, n (%) | 285 (62.4) | |
| Age, years (mean ± SD) | 43.1 ± 12.5 | |
| Time since diagnosis, years (mean ± SD) | 8.3 ± 8.5 | |
| Current symptomsa | ||
| PRO2 score (mean ± SD) | 1.4 ± 1.4 | |
| PRO2 remissionb [n (%)] | 263 (57.5) | |
| Therapeutic drug | Most recent UC relapse | Current |
| 5-ASA (enema/suppository) [n (%)] | 135 (29.5) | 117 (25.6) |
| 5-ASA (oral) [n (%)] | 253 (55.4) | 371 (81.2) |
| Corticosteroid (enema) [n (%)] | 144 (31.5) | 71 (15.5) |
| Corticosteroid (oral) [n (%)] | 167 (36.5) | 59 (12.9) |
| Corticosteroid (IV) [n (%)] | 49 (10.7) | 4 (0.9) |
| Immunomodulator (oral) [n (%)] | 73 (16.0) | 85 (18.6) |
| Immunomodulator (IV) [n (%)] | 6 (1.3) | 0 (0) |
| Biologic agent [n (%)] | 90 (19.7) | 124 (27.1) |
| JAK inhibitor [n (%)] | 14 (3.1) | 12 (2.6) |
| Other [n (%)] | 42 (9.2) | 53 (11.6) |
| Healthcare institutions where the treatment plan was selected at the time of UC relapse | ||
| National and public hospitals [n (%)] | 105 (23.0) | |
| University hospital [n (%)] | 132 (28.9) | |
| Clinic [n (%)] | 81 (17.7) | |
| Otherc [n (%)] | 139 (30.4) | |
| Time spent with the physician, min | When deciding on treatment | During routine clinical care |
| < 5 [n (%)] | 47 (10.3) | 112 (24.5) |
| 5 to < 10 [n (%)] | 147 (32.2) | 208 (45.5) |
| 10 to < 15 [n (%)] | 133 (29.1) | 96 (21.0) |
| 15 to < 30 [n (%)] | 73 (16.0) | 26 (5.7) |
| ≥ 30 [n (%)] | 57 (12.5) | 15 (3.3) |
| Patient decision-making preference scale (mean ± SD) | 2.6 ± 0.4 | |
ASA aminosalicylate, IV intravenous, JAK Janus kinase, PRO2 two-item patient-reported outcomes, UC ulcerative colitis
aSymptoms in the last 3 days
bPRO2 remission was defined as bleeding = 0 and stool frequency ≤ 1
cHospital other than a national and public hospital or university hospital